What was the market valuation of the US fabry disease market in 2024?

The market valuation of the US fabry disease market was $511.72 Million in 2024. Read More

What is the projected market valuation for the US fabry disease market by 2035?

The projected market valuation for the US fabry disease market is $1171.47 Million by 2035. Read More

What is the expected CAGR for the US fabry disease market during the forecast period 2025 - 2035?

The expected CAGR for the US fabry disease market during the forecast period 2025 - 2035 is 7.82%. Read More

Which companies are key players in the US fabry disease market?

Key players in the US fabry disease market include Sanofi, Amicus Therapeutics, Takeda Pharmaceutical Company, Genzyme, Pfizer, Sobi, Bayer, and Janssen Pharmaceuticals. Read More

What are the market segments for the US fabry disease market?

The market segments for the US fabry disease market include Type, Diagnosis, Treatment, and End Users. Read More

What was the market size for Type 1 and Type 2 fabry disease treatments in 2024?

In 2024, the market size for Type 1 treatments was $307.03 Million, while Type 2 treatments were valued at $204.69 Million. Read More

What are the projected values for enzyme replacement therapy in the US fabry disease market?

The projected values for enzyme replacement therapy in the US fabry disease market range from $200.0 Million to $450.0 Million. Read More

How much is expected to be spent on diagnostic tests for fabry disease in 2035?

By 2035, spending on diagnostic tests for fabry disease is expected to reach between $286.72 Million and $591.47 Million. Read More

What is the anticipated market size for hospitals and clinics as end users in the US fabry disease market?

The anticipated market size for hospitals and clinics as end users in the US fabry disease market is projected to be between $200.0 Million and $450.0 Million. Read More

What is the expected growth trend for pharmaceutical treatments containing Agalsidase Alfa?

The expected growth trend for pharmaceutical treatments containing Agalsidase Alfa is projected to range from $100.0 Million to $250.0 Million. Read More

US Fabry Disease Market

US Fabry Disease Market Research Report: Size, Share, Trend Analysis By Types (Type 1, Type 2) By Diagnosis (Blood Test, Urine Test, Thyroid Test, Lung Function Test, Imaging, Hearing and Eye Examination, Others) By End Userss (Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Others) By Treatment (Enzyme Replacement Therapy, Gene Therapy, Pharmaceutical Treatments containing Agalsidase Alfa, Analgesics, Anticonvulsants, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Others) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.82%

2024 Market Size

$ 511.72 Million

2035 Market Size

$ 1,171.47 Million

Healthcare ● Updated January 2026 Report ID: MRFR/HC/16514-CR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Type 1
  2. 4.1.2 Type 2
2. 4.2 Construction, BY Diagnosis (USD Million)
  1. 4.2.1 Blood Test
  2. 4.2.2 Urine Test
  3. 4.2.3 Thyroid Test
  4. 4.2.4 Lung Function Test
  5. 4.2.5 Imaging
  6. 4.2.6 Hearing and Eye Examination
  7. 4.2.7 Others
3. 4.3 Construction, BY Treatment (USD Million)
  1. 4.3.1 Enzyme Replacement Therapy
  2. 4.3.2 Gene Therapy
  3. 4.3.3 Pharmaceutical Treatments containing Agalsidase Alfa
  4. 4.3.4 Analgesics
  5. 4.3.5 Anticonvulsants
  6. 4.3.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  7. 4.3.7 Others
4. 4.4 Construction, BY End Users (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Research & Academic Institutes
  4. 4.4.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Sanofi (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amicus Therapeutics (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Genzyme (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sobi (SE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bayer (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Janssen Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END USERS
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USERS, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USERS, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USERS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

Type 1
Type 2

Construction By Diagnosis (USD Million, 2025-2035)

Blood Test
Urine Test
Thyroid Test
Lung Function Test
Imaging
Hearing and Eye Examination
Others

Construction By Treatment (USD Million, 2025-2035)

Enzyme Replacement Therapy
Gene Therapy
US Fabry Disease Market Treatments containing Agalsidase Alfa
Analgesics
Anticonvulsants
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Others

Construction By End Users (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Research & Academic Institutes
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”